Table 3 Associations between HCW self-reported symptoms and SARS-CoV-2 seropositivity of HCW study population and subgroups segregated by prior rt-PCR testing
|  | All HCWs (n = 1,557) | Not tested by rt-PCR (n = 1,138) | Tested by rt-PCR (n = 419) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | HCWs, n (%) | COVID-19 AB prevalence, n (%) | Adjusted OR (95% CI)1 | HCWs, n (%) | COVID-19 AB prevalence, n (%) | Adjusted OR (95% CI)1 | HCWs, n (%) | COVID-19 AB prevalence, n (%) | Adjusted OR (95% CI)1 |
Total | 1557 (100) | 165 (10.6) | Â | 1138 (100) | 91 (8.0) | Â | 419 (100) | 74 (17.7) | Â |
Symptoms 2 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Sore throat | 633 (40.7) | 79 (12.5) | 1.38 (1.00-1.92) | 405 (35.6) | 41 (10.1) | 1.47 (0.95–2.27) | 228 (54.4) | 38 (16.7) | 0.95 (0.56–1.60) |
Fatigue | 429 (27.6) | 63 (14.7) | 1.77 (1.25–2.49) | 244 (21.4) | 17 (7.0) | 0.79 (0.44–1.35) | 185 (44.2) | 46 (24.9) | 2.94 (1.72–5.12) |
Muscle aches | 361 (23.2) | 55 (15.2) | 1.76 (1.23–2.50) | 198 (17.4) | 15 (7.6) | 0.89 (0.48–1.56) | 163 (38.9) | 40 (24.5) | 2.20 (1.30–3.74) |
New cough | 470 (30.2) | 54 (11.5) | 1.11 (0.78–1.57) | 292 (25.7) | 18 (6.2) | 0.65 (0.36–1.09) | 178 (42.5) | 36 (20.2) | 1.50 (0.89–2.53) |
New chills | 327 (21.0) | 51 (15.6) | 1.79 (1.24–2.55) | 183 (16.1) | 12 (6.6) | 0.74 (0.37–1.34) | 144 (34.4) | 39 (27.1) | 2.61 (1.55–4.44) |
Fever | 318 (20.4) | 48 (15.1) | 1.67 (1.15–2.39) | 177 (15.6) | 11 (6.2) | 0.67 (0.33–1.24) | 141 (33.7) | 37 (26.2) | 2.38 (1.40–4.04) |
Anosmia | 95 (6.1) | 33 (34.7) | 5.34 (3.33–8.45) | 40 (3.5) | 5 (12.5) | 1.67 (0.56–4.08) | 55 (13.1) | 28 (50.9) | 7.67 (4.05–14.76) |
Dyspnea | 200 (12.8) | 27 (13.5) | 1.38 (0.87–2.13) | 113 (9.9) | 8 (7.1) | 0.83 (0.36–1.68) | 87 (20.8) | 19 (21.8) | 1.61 (0.86–2.91) |